Spirocyclic O-GlcNAcase Inhibitors for Selective Tau Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Developing selective inhibitors for O-GlcNAcase to treat Alzheimer's disease and related tauopathies is challenging due to the non-specific inhibition of functionally related enzymes, leading to complex phenotypes.

Innovation Solution

Compounds represented by specific structural formulas are developed to selectively inhibit O-GlcNAcase, which are useful in treating diseases associated with O-GlcNAc-modified proteins, including Alzheimer's disease and tauopathies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If non-selective inhibitors are used to block O-GlcNAcase function, then inhibition of O-GlcNAcase is achieved, but lysosomal beta-hexosaminidases are also inhibited leading to complex phenotypes

Engineering Contradiction:

Improveinhibition efficacyVSAvoidselectivity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by designing inhibitors with specific molecular features (spirocyclic structures with particular substituents at defined positions) that confer selectivity for O-GlcNAcase over other beta-hexosaminidases. The compounds have specific structural characteristics (Y1 and Y2 being CRc or N with at least one being N, specific R1-R4 substituents, and D-E linkages) that enable selective binding to O-GlcNAcase while avoiding off-target effects on lysosomal enzymes.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by systematically varying molecular parameters of the inhibitor compounds including the identity of Y1 and Y2, the nature of R1-R4 substituents, the D-E linkage type, and the spirocyclic ring structure. These parameter variations are optimized to achieve the desired balance between potent O-GlcNAcase inhibition and selectivity against lysosomal beta-hexosaminidases.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If existing beta-N-acetylglucosaminidase inhibitors are used, then O-GlcNAcase function is blocked, but functionally related enzymes are also inhibited

Engineering Contradiction:

Improveinhibition potencyVSAvoidoff-target effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the potential harm of off-target inhibition into a benefit by designing compounds that exploit the specific structural features of O-GlcNAcase to achieve selective inhibition. The spirocyclic core structure with specific substituent patterns is designed to match the unique binding pocket characteristics of O-GlcNAcase, transforming the challenge of enzyme similarity into an opportunity for selective drug design.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent uses the spirocyclic molecular structure as an intermediary that mediates selective interaction between the inhibitor and O-GlcNAcase. The specific molecular architecture acts as a bridge that enables selective binding to O-GlcNAcase while preventing interaction with lysosomal beta-hexosaminidases, thereby resolving the contradiction between potency and selectivity.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12565504B2Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Publication Date: 2026.03.03 BIOGEN MA INC

AI summary

Described herein are compounds represented by formula (I) or formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R2, R3, R4, R5, R6, Y1, Y2, D, E, G1, G2, n and p are as defined herein.